Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.60 |
| ▸ | HTR1D | P28221 | 14/20 | 0.60 |
| ▸ | HTR1B | P28222 | 14/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179466 | 0.90 | HTR1A (0.74) | HTR1AHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL6179304 | 0.78 | HTR1A (0.64) | HTR1AHTR1DHTR1BMAPTNFKB1 | |
| SCHEMBL6212175 | 0.73 | HTR1A (0.62) | HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL6370192 | 0.72 | HTR1A (0.84) | HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL6179764 | 0.72 | HTR2C (0.51) | HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL6180945 | 0.71 | HTR1A (0.46) | HTR1AHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL27542472 | 0.71 | HTR1D (0.74) | HTR1AHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL27536404 | 0.71 | HTR1A (0.82) | HTR1AHTR1DHTR1BCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL8130752 | 0.70 | HTR1D (0.73) | HTR1AHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL16647211 | 0.69 | HTR2C (0.58) | HTR1AHTR1DHTR1BCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | SMITHKLINE BEECHAM, PLC | 2005-10-27 | — | — | US | disclosed |
| EP-1228043-B1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | HTR1B, HTR1A, HTR1D | HTR1A 2/4885HTR1D 3/4885HTR1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.